Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2003 Apr;79(930):195–200. doi: 10.1136/pmj.79.930.195

Mechanisms of oxidative stress and vascular dysfunction

Z Nedeljkovic 1, N Gokce 1, J Loscalzo 1
PMCID: PMC1742679  PMID: 12743334

Abstract

The endothelium regulates vascular homoeostasis through local elaboration of mediators that modulate vascular tone, platelet adhesion, inflammation, fibrinolysis, and vascular growth. Impaired vascular function contributes to the pathogenesis of atherosclerosis and acute coronary syndromes. There is growing pathophysiological evidence that increased generation of reactive oxygen species and oxidative stress participates in proatherogenic mechanisms of vascular dysfunction and atherothrombosis. In this review, the role of oxidative stress in mechanisms of vascular dysfunction is discussed, and potential antioxidant strategies are reviewed.

Full Text

The Full Text of this article is available as a PDF (115.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azumi Hiroshi, Inoue Nobutaka, Ohashi Yoshitaka, Terashima Mitsuyasu, Mori Takao, Fujita Hideki, Awano Kojiro, Kobayashi Katsuya, Maeda Kazumi, Hata Katsuya. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1838–1844. doi: 10.1161/01.atv.0000037101.40667.62. [DOI] [PubMed] [Google Scholar]
  2. Berliner J. A., Heinecke J. W. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996;20(5):707–727. doi: 10.1016/0891-5849(95)02173-6. [DOI] [PubMed] [Google Scholar]
  3. Brown B. G., Zhao X. Q., Chait A., Fisher L. D., Cheung M. C., Morse J. S., Dowdy A. A., Marino E. K., Bolson E. L., Alaupovic P. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001 Nov 29;345(22):1583–1592. doi: 10.1056/NEJMoa011090. [DOI] [PubMed] [Google Scholar]
  4. Cai H., Harrison D. G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000 Nov 10;87(10):840–844. doi: 10.1161/01.res.87.10.840. [DOI] [PubMed] [Google Scholar]
  5. Cardillo C., Kilcoyne C. M., Cannon R. O., 3rd, Quyyumi A. A., Panza J. A. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 1997 Jul;30(1 Pt 1):57–63. doi: 10.1161/01.hyp.30.1.57. [DOI] [PubMed] [Google Scholar]
  6. Channon Keith M. Oxidative stress and coronary plaque stability. Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1751–1752. doi: 10.1161/01.atv.0000042203.08210.17. [DOI] [PubMed] [Google Scholar]
  7. Chin J. H., Azhar S., Hoffman B. B. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest. 1992 Jan;89(1):10–18. doi: 10.1172/JCI115549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Diaz M. N., Frei B., Vita J. A., Keaney J. F., Jr Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997 Aug 7;337(6):408–416. doi: 10.1056/NEJM199708073370607. [DOI] [PubMed] [Google Scholar]
  9. Galis Z. S., Asanuma K., Godin D., Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation. 1998 Jun 23;97(24):2445–2453. doi: 10.1161/01.cir.97.24.2445. [DOI] [PubMed] [Google Scholar]
  10. Galis Z. S., Sukhova G. K., Lark M. W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994 Dec;94(6):2493–2503. doi: 10.1172/JCI117619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gokce N., Keaney J. F., Jr, Frei B., Holbrook M., Olesiak M., Zachariah B. J., Leeuwenburgh C., Heinecke J. W., Vita J. A. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1999 Jun 29;99(25):3234–3240. doi: 10.1161/01.cir.99.25.3234. [DOI] [PubMed] [Google Scholar]
  12. Griendling K. K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000 Mar 17;86(5):494–501. doi: 10.1161/01.res.86.5.494. [DOI] [PubMed] [Google Scholar]
  13. Gryglewski R. J., Palmer R. M., Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986 Apr 3;320(6061):454–456. doi: 10.1038/320454a0. [DOI] [PubMed] [Google Scholar]
  14. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001 Nov 27;104(22):2673–2678. doi: 10.1161/hc4601.099485. [DOI] [PubMed] [Google Scholar]
  15. Irani K. Oxidant signaling in vascular cell growth, death, and survival : a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000 Aug 4;87(3):179–183. doi: 10.1161/01.res.87.3.179. [DOI] [PubMed] [Google Scholar]
  16. Kojda G., Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999 Aug 15;43(3):562–571. doi: 10.1016/s0008-6363(99)00169-8. [DOI] [PubMed] [Google Scholar]
  17. Kunsch C., Medford R. M. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999 Oct 15;85(8):753–766. doi: 10.1161/01.res.85.8.753. [DOI] [PubMed] [Google Scholar]
  18. Laursen J. B., Rajagopalan S., Galis Z., Tarpey M., Freeman B. A., Harrison D. G. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997 Feb 4;95(3):588–593. doi: 10.1161/01.cir.95.3.588. [DOI] [PubMed] [Google Scholar]
  19. Lonn E., Yusuf S., Dzavik V., Doris C., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W., Teo K. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001 Feb 20;103(7):919–925. doi: 10.1161/01.cir.103.7.919. [DOI] [PubMed] [Google Scholar]
  20. Ludmer P. L., Selwyn A. P., Shook T. L., Wayne R. R., Mudge G. H., Alexander R. W., Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986 Oct 23;315(17):1046–1051. doi: 10.1056/NEJM198610233151702. [DOI] [PubMed] [Google Scholar]
  21. Mancini G. B., Henry G. C., Macaya C., O'Neill B. J., Pucillo A. L., Carere R. G., Wargovich T. J., Mudra H., Lüscher T. F., Klibaner M. I. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996 Aug 1;94(3):258–265. doi: 10.1161/01.cir.94.3.258. [DOI] [PubMed] [Google Scholar]
  22. Mügge A., Elwell J. H., Peterson T. E., Harrison D. G. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol. 1991 Feb;260(2 Pt 1):C219–C225. doi: 10.1152/ajpcell.1991.260.2.C219. [DOI] [PubMed] [Google Scholar]
  23. Münzel T., Keaney J. F., Jr Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation. 2001 Sep 25;104(13):1571–1574. doi: 10.1161/hc3801.095585. [DOI] [PubMed] [Google Scholar]
  24. Navab M., Imes S. S., Hama S. Y., Hough G. P., Ross L. A., Bork R. W., Valente A. J., Berliner J. A., Drinkwater D. C., Laks H. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991 Dec;88(6):2039–2046. doi: 10.1172/JCI115532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ohara Y., Peterson T. E., Harrison D. G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993 Jun;91(6):2546–2551. doi: 10.1172/JCI116491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rajagopalan S., Kurz S., Münzel T., Tarpey M., Freeman B. A., Griendling K. K., Harrison D. G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996 Apr 15;97(8):1916–1923. doi: 10.1172/JCI118623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schächinger V., Britten M. B., Zeiher A. M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000 Apr 25;101(16):1899–1906. doi: 10.1161/01.cir.101.16.1899. [DOI] [PubMed] [Google Scholar]
  28. Sorescu Dan, Weiss Daiana, Lassègue Bernard, Clempus Roza E., Szöcs Katalin, Sorescu George P., Valppu Liisa, Quinn Mark T., Lambeth J. David, Vega J. David. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002 Mar 26;105(12):1429–1435. doi: 10.1161/01.cir.0000012917.74432.66. [DOI] [PubMed] [Google Scholar]
  29. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989 Apr 6;320(14):915–924. doi: 10.1056/NEJM198904063201407. [DOI] [PubMed] [Google Scholar]
  30. Steinberg Daniel, Witztum Joseph L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 2002 Apr 30;105(17):2107–2111. doi: 10.1161/01.cir.0000014762.06201.06. [DOI] [PubMed] [Google Scholar]
  31. Stephens N. G., Parsons A., Schofield P. M., Kelly F., Cheeseman K., Mitchinson M. J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) Lancet. 1996 Mar 23;347(9004):781–786. doi: 10.1016/s0140-6736(96)90866-1. [DOI] [PubMed] [Google Scholar]
  32. Stroes E., Kastelein J., Cosentino F., Erkelens W., Wever R., Koomans H., Lüscher T., Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997 Jan 1;99(1):41–46. doi: 10.1172/JCI119131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Takemoto M., Liao J. K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1712–1719. doi: 10.1161/hq1101.098486. [DOI] [PubMed] [Google Scholar]
  34. Timimi F. K., Ting H. H., Haley E. A., Roddy M. A., Ganz P., Creager M. A. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1998 Mar 1;31(3):552–557. doi: 10.1016/s0735-1097(97)00536-6. [DOI] [PubMed] [Google Scholar]
  35. Ueda S., Matsuoka H., Miyazaki H., Usui M., Okuda S., Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol. 2000 Jan;35(1):71–75. doi: 10.1016/s0735-1097(99)00523-9. [DOI] [PubMed] [Google Scholar]
  36. Valen G., Yan Z. Q., Hansson G. K. Nuclear factor kappa-B and the heart. J Am Coll Cardiol. 2001 Aug;38(2):307–314. doi: 10.1016/s0735-1097(01)01377-8. [DOI] [PubMed] [Google Scholar]
  37. Vane J. R., Anggård E. E., Botting R. M. Regulatory functions of the vascular endothelium. N Engl J Med. 1990 Jul 5;323(1):27–36. doi: 10.1056/NEJM199007053230106. [DOI] [PubMed] [Google Scholar]
  38. Vita J. A., Treasure C. B., Nabel E. G., McLenachan J. M., Fish R. D., Yeung A. C., Vekshtein V. I., Selwyn A. P., Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990 Feb;81(2):491–497. doi: 10.1161/01.cir.81.2.491. [DOI] [PubMed] [Google Scholar]
  39. Witztum J. L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991 Dec;88(6):1785–1792. doi: 10.1172/JCI115499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wolin M. S. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1430–1442. doi: 10.1161/01.atv.20.6.1430. [DOI] [PubMed] [Google Scholar]
  41. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):154–160. doi: 10.1056/NEJM200001203420302. [DOI] [PubMed] [Google Scholar]
  42. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145–153. doi: 10.1056/NEJM200001203420301. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES